Acalabrutinib- Anti-cancer drug- (Calquence - 2017)
List Of Brands:
Indication Type Description:
INDICATIONS AND USAGE
CALQUENCE is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
DOSAGE AND ADMINISTRATION
Recommended dose is 100 mg orally approximately every twelve hours; swallow whole with water and with or without food.
Advise patients not to break, open, or chew capsules.
Manage toxicities using treatment interruption, dose reduction, or discontinuation.
Disclaimer: Every effort has been made to ensure that the information provided in
this Database is authentic and accurate. Commissions or omissions in the database,
if any, are purely inadvertent and the site owner shall not accept any liability
whatsoever for any adverse consequences of any nature arising to any individual
or third party, as a result of usage of this information.